Mirati Therapeutics Target Price

Explore Mirati Therapeutics's target price with historical charts and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Share Price

$58.7

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2022-12-14	Morgan Stanley	$60	2.2% upside
2022-12-14	Leerink Partners	$75	27.8% upside
2022-12-13	Piper SandlerSwapnil Malekar	$68	15.8% upside
2022-12-13	Piper Sandler	$87	48.2% upside
2022-12-09	Citigroup	$53	9.7% downside
2022-12-08	Leerink Partners	$85	44.8% upside
2022-12-08	Oppenheimer	$60	2.2% upside
2022-12-08	J.P. Morgan	$65	10.7% upside
2022-12-07	BMO CapitalEvan Seigerman	$59	0.5% upside
2022-12-07	Piper SandlerSwapnil Malekar	$84	43.1% upside
2022-02-01	Bank of America SecuritiesJason Gerberry	$141	140.2% upside
2021-09-21	H.C. WainwrightEdward White	$247	320.8% upside
2021-09-20	JefferiesMaury Raycroft	$193	228.8% upside

Mirati Therapeutics (MRTX) FAQ

Stockcircle tracks target price for Mirati Therapeutics (MRTX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Target Price page is built for Mirati Therapeutics's historical target price trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use target price as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main MRTX overview so you can move from this figure to the surrounding analysis quickly.